Multi-target Compounds against Trypanosomatid Parasites and Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Multi-target Compounds against Trypanosomatid Parasites and Mycobacterium tuberculosis

Published:2024-07 Issue:9 Volume:25 Page:602-619
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

Gomes Midiane Correia¹^ORCID,Padilha Emanuelly Karla Araújo¹^ORCID,Diniz Gustavo Rafael Angelo¹,Gomes Edilma Correia¹,da Silva Santos-Júnior Paulo Fernando¹,Zhan Peng²,da Siva-Júnior Edeildo Ferreira¹^ORCID

Affiliation:

1. Research Group in Biological and Molecular Chemistry, Institute of Chemistry and Biotechnology, Federal University of Alagoas, Campus AC. Simões, CEP 57072-970, Maceió-AL, Brazil

2. Department of Medicinal - Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, 250012 Jinan, Shandong, P.R. China

Abstract

: Multi-target drug treatment has become popular as a substitute for traditional monotherapy. Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected to be an important development in the pharmaceutical industry in the near future. This review presents multi-target compounds against trypanosomatid parasites (Trypanosoma cruzi, T. brucei, and Leishmania sp.) and tuberculosis (Mycobacterium tuberculosis), which mainly affect populations in socioeconomically unfavorable conditions. The article analyzes the studies, including their chemical structures, viral strains, and molecular docking studies, when available. The objective of this review is to establish a foundation for designing new multi-target inhibitors for these diseases.

Publisher

Bentham Science Publishers Ltd.